Estimates of the worldwide frequency of sixteen major cancers in 1980

Abstract

The numbers of new cancer cases in 16 common sites occurring in 1980 have been estimated for 24 areas of the world for which the United Nations produces population estimates. For the world as a whole, the total number of new cases was 6.35 million, almost exactly evenly divided between the developed and developing countries. In males, the most important sites were lung, stomach, colon/rectum, mouth/pharynx, prostate and oesophagus, and in females breast, cervix, colon/rectum, stomach, corpus uteri and lung. When the two sexes are combined, stomach cancer emerges as the most common cancer in 1980 (669,400 new cases per year), but this estimate is only slightly greater than that of lung cancer (660,500 new cases), and comparisons with earlier estimates for 1975 suggest that, with declining incidence rates for stomach cancer and the continuing rise for lung cancer, the latter would become the most common cancer in the world by the end of 1981. The implications for cancer control in the developed and developing countries of the world are discussed.

Re-expression of endogenous p16ink4a in oral squamous cell carcinoma lines by 5-aza-2′-deoxycytidine treatment induces a senescence-like state

“…Head and neck cancers are the sixth most common malignancy worldwide (Parkin et al, 1988). Generally, these carcinomas are accessible for early diagnosis, but they are associated with a high rate of mortality (Fernandez-Martinez et al, 1995), indicating the need for improved cancer therapy and a better understanding of the molecular changes underlying cancer development.…”

Centrosomal abnormalities, multipolar mitoses, and chromosomal instability in head and neck tumours with dysfunctional telomeres

“…Carcinoma of the head and neck is the sixth most common malignancy world-wide (Parkin et al, 1988). Whereas tumours confined to the oral cavity and the airways are predominantly squamous cell carcinomas, tumours of the salivary glands are histologically more heterogeneous, with the most common type being pleomorphic adenoma (PA).…”

Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer

“…1 The estimated number of cases worldwide is ϳ140,000. 2 The initial chemotherapy for ovarian cancer usually includes the drugs cisplatin or carboplatin in a regimen combined with paclitaxel or cyclophosphamide. Up to 73% of patients with stage III and IV tumors respond to this therapy.…”